Evidence map›Paper›PMID 42406649›Full record

ArticleACS applied materials & interfaces2026

Tiered Evaluation of Carbosilane Dendrimer-siRNA Nanoplatform from Single-Cell Biocompatibility to Blood-Brain Barrier Model Dynamics and Murine Alzheimer Model Behavior Assessment.

Serafin Zawadzki, Elżbieta Okła, Sylwia Michlewska, Radosław Bednarek, Paula Ortega López, F Javier de la Mata, Juris Jansons, Dace Skrastina, Madara Kreišmane, Vladimirs Piļipenko and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Serafin ZawadzkiDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., Lodz 90-236, Poland.ORCID 0000-0002-3093-5945
Elżbieta OkłaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., Lodz 90-236, Poland.
Sylwia MichlewskaLaboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, Lodz 90-237, Poland.ORCID 0000-0002-8952-469X
Radosław BednarekDepartment of Cytobiology and Proteomics, Medical University of Lodz, Lodz 92-215, Poland.ORCID 0000-0003-4505-9498
Paula Ortega LópezDepartment of Organic and Inorganic Chemistry, IQAR, University of Alcalá, Madrid 28805, Spain.ORCID 0000-0003-0377-5429
F Javier de la MataDepartment of Organic and Inorganic Chemistry, IQAR, University of Alcalá, Madrid 28805, Spain.ORCID 0000-0003-0418-3935
Juris JansonsLatvian Biomedical Research and Study Centre, Ratsupites str 1 k-1, Riga 1067, Latvia.ORCID 0000-0003-0845-4392
Dace SkrastinaLatvian Biomedical Research and Study Centre, Ratsupites str 1 k-1, Riga 1067, Latvia.
Madara KreišmaneLatvian Biomedical Research and Study Centre, Ratsupites str 1 k-1, Riga 1067, Latvia.
Vladimirs PiļipenkoDepartment of Neuromedicine and Neuroscience, Faculty of Medicine and Life Sciences, University of Latvia, Jelgavas street 3, Riga 1067, Latvia.
Baiba JansoneDepartment of Neuromedicine and Neuroscience, Faculty of Medicine and Life Sciences, University of Latvia, Jelgavas street 3, Riga 1067, Latvia.
Maksim IonovDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., Lodz 90-236, Poland.ORCID 0000-0001-7227-6864
Maria BryszewskaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., Lodz 90-236, Poland.
Katarzyna MiłowskaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., Lodz 90-236, Poland.ORCID 0000-0002-4050-2756

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood-brain barrier (BBB) transport remains a primary constraint on achieving predictable central nervous system exposure for Alzheimer's disease (AD) therapeutics, motivating the evaluation of delivery platforms with barrier-resolved and functionally relevant end points. We assessed a carbosilane dendrimer (G3Si PEG6000) and its siRNA dendriplex using a tiered, upstream strategy spanning cell internalization, DNA damage screening, BBB model integrity and permeability, and

Indexed as

Alzheimer DiseaseBiocompatible MaterialsBlood-Brain BarrierDendrimersRNA, Small InterferingSilanesAnimalsDisease Models, AnimalHumansMiceBiocompatible MaterialscarbosilaneDendrimersRNA, Small InterferingSilanesAlzheimer’s diseasebehavioral assessmentblood−brain barrier modelcarbosilane dendrimernanoparticlessiRNA

Identifiers

PMID42406649
PMCPMC13383278

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.